CONFERENCE UPDATE : ESMO2020
Frontline pembrolizumab plus chemotherapy significantly improves survival compared with chemotherapy alone in patients with locally advanced unresectable or metastatic esophageal cancer
Nivolumab plus ipilimumab nearly doubling the response rates for women with recurrent/persistent ovarian cancer compared to nivolumab monotherapy
Despite an 80% overall response rate to primary platinum-based chemotherapy, a high proportion of women experience disease recurrence.1 At present, there is no known gold standard for the second‐line treatment of ovarian cancer.
First-line treatment with immunotherapy in metastatic squamous NSCLC
Immunotherapy has dramatically changed the therapeutic scenario in the treatment-naïve advanced NSCLC. While the single agent pembrolizumab has become the standard first-line therapy in patients with ≥50% PD-L1 expression on tumor cells,